| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aimee L McRae-Clark, Kevin M Gray, Nathaniel L Baker, Brian J Sherman, Lindsay Squeglia, Gregory L Sahlem, Amanda Wagner, Rachel Tomk. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug and alcohol dependence. vol 229. issue Pt B. 2021-12-12. PMID:34655945. |
an efficacious pharmacotherapy for cannabis use disorder (cud) has yet to be established. |
2021-12-12 |
2023-08-13 |
Not clear |
| Sarah Gutkind, David S Fink, Dvora Shmulewitz, Malka Stohl, Deborah Hasi. Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S. adults. Drug and alcohol dependence. vol 229. issue Pt B. 2021-12-12. PMID:34763137. |
although the problems associated with alcohol use disorder (aud) are well known, little is known about the psychosocial problems associated with cannabis use disorder (cud), and the harmfulness of cud relative to aud. |
2021-12-12 |
2023-08-13 |
Not clear |
| Kristine Rømer Thomsen, Birgitte Thylstrup, Emily A Kenyon, Rachel Lees, Lone Baandrup, Sarah W Feldstein Ewing, Tom P Freema. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? Neuroscience and biobehavioral reviews. vol 132. 2021-12-11. PMID:34822876. |
cannabis use peaks during adolescence and emerging adulthood, and cannabis use disorder (cud) is associated with a wide range of adverse outcomes. |
2021-12-11 |
2023-08-13 |
Not clear |
| Kristine Rømer Thomsen, Birgitte Thylstrup, Emily A Kenyon, Rachel Lees, Lone Baandrup, Sarah W Feldstein Ewing, Tom P Freema. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? Neuroscience and biobehavioral reviews. vol 132. 2021-12-11. PMID:34822876. |
preliminary evidence from two placebo-controlled rcts in adults with cud suggests that both fatty acid amide hydrolase inhibitors and cbd can reduce cannabis use. |
2021-12-11 |
2023-08-13 |
Not clear |
| Adeolu Funso Oladunjoye, Syed Zane Kaleem, Aishwarya Suresh, Vikram Sahni, Matthew J Thoonkuzhy, Gibson Anugwom, Olubunmi Oladunjoye, David Otuada, Joseph Ikekwere, Eduardo D Espiridio. Cannabis use and medication nonadherence in bipolar disorder: A nationwide inpatient sample database analysis. Journal of affective disorders. vol 299. 2021-12-11. PMID:34863715. |
this study aims to investigate cannabis use disorder (cud) association with medication noncompliance in hospitalized bd patients. |
2021-12-11 |
2023-08-13 |
Not clear |
| Michael A Russell, Rachel N Bomysoad, J Douglas Coatsworth, Michael J Maso. Effects of a cannabis use disorder text message-delivered treatment on young adult alcohol misuse: Differential effects by gender. Journal of substance abuse treatment. vol 132. 2021-12-10. PMID:34111771. |
in the current study, we present a secondary analysis of a randomized clinical trial testing a text message-delivered cannabis use disorder (cud) treatment (peer network counseling text or "pnc-txt"). |
2021-12-10 |
2023-08-13 |
Not clear |
| Sushupta M Vijapur, Natalie S Levy, Silvia S Martin. Cannabis use outcomes by past-month binge drinking status in the general United States population. Drug and alcohol dependence. vol 228. 2021-12-10. PMID:34508962. |
cannabis outcomes included past-month and past-year use, daily/almost daily use, and past-year dsm-iv/dsm-5 cannabis use disorder (cud). |
2021-12-10 |
2023-08-13 |
Not clear |
| Sushupta M Vijapur, Natalie S Levy, Silvia S Martin. Cannabis use outcomes by past-month binge drinking status in the general United States population. Drug and alcohol dependence. vol 228. 2021-12-10. PMID:34508962. |
the adjusted odds of dsm-iv and dsm-5 cud among people who used cannabis were 15 % and 12 % higher among people who engaged in binge drinking than those who did not, respectively (or: 1.15, 95 %ci: 1.05, 1.26 and or: 1.12, 95 %ci: 1.03, 1.21). |
2021-12-10 |
2023-08-13 |
Not clear |
| James G Linakis, Sarah A Thomas, Julie R Bromberg, T Charles Casper, Thomas H Chun, Michael J Mello, Rachel Richards, Fahd Ahmad, Lalit Bajaj, Kathleen M Brown, Lauren S Chernick, Daniel M Cohen, J Michael Dean, Joel Fein, Timothy Horeczko, Michael N Levas, B McAninch, Michael C Monuteaux, Colette C Mull, Jackie Grupp-Phelan, Elizabeth C Powell, Alexander Rogers, Rohit P Shenoi, Brian Suffoletto, Cheryl Vance, Anthony Spirit. Adolescent alcohol use predicts cannabis use over a three year follow-up period. Substance abuse. 2021-12-08. PMID:34236277. |
alcohol and cannabis use frequently co-occur, which can result in problems from social and academic impairment to dependence (i.e., alcohol use disorder [aud] and/or cannabis use disorder [cud]). |
2021-12-08 |
2023-08-13 |
Not clear |
| James G Linakis, Sarah A Thomas, Julie R Bromberg, T Charles Casper, Thomas H Chun, Michael J Mello, Rachel Richards, Fahd Ahmad, Lalit Bajaj, Kathleen M Brown, Lauren S Chernick, Daniel M Cohen, J Michael Dean, Joel Fein, Timothy Horeczko, Michael N Levas, B McAninch, Michael C Monuteaux, Colette C Mull, Jackie Grupp-Phelan, Elizabeth C Powell, Alexander Rogers, Rohit P Shenoi, Brian Suffoletto, Cheryl Vance, Anthony Spirit. Adolescent alcohol use predicts cannabis use over a three year follow-up period. Substance abuse. 2021-12-08. PMID:34236277. |
the current study, a secondary data analysis, assessed the relationship between adolescent alcohol and cannabis use by examining the national institute of alcohol abuse and alcoholism (niaaa) two question screen's (2qs) ability to predict future cud at one, two, and three years post-ed visit. |
2021-12-08 |
2023-08-13 |
Not clear |
| Helen S Ullrich, Autena Torbati, Weihua Fan, Consuelo Arbona, Miguel A Cano, Saman Essa, Laura Harvey, Ellen L Vaughan, Marcel A de Dio. Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: A latent profile analysis based on preferred method of using cannabis. Journal of substance abuse treatment. vol 131. 2021-12-07. PMID:34275690. |
there are a wide variety of methods for using combustible cannabis which may impact an individual's pattern of use as well as their response to cannabis use disorder (cud) treatment. |
2021-12-07 |
2023-08-13 |
Not clear |
| Alexander S Hatoum, Emma C Johnson, Sarah M C Colbert, Renato Polimanti, Hang Zhou, Raymond K Walters, Joel Gelernter, Howard J Edenberg, Ryan Bogdan, Arpana Agrawa. The addiction risk factor: A unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2021-12-07. PMID:34750568. |
we tested whether a common genetic factor undergirds liability to problematic alcohol use (pau), problematic tobacco use (ptu), cannabis use disorder (cud), and opioid use disorder (oud) by applying genomic structural equation modeling to genome-wide association study summary statistics for individuals of european ancestry (total n = 1,019,521; substance-specific ns range: 82,707-435,563) while adjusting for the genetics of substance use (ns = 184,765-632,802). |
2021-12-07 |
2023-08-13 |
Not clear |
| Erin L Martin, Aimee L McRae-Clar. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Current addiction reports. vol 7. 2021-12-03. PMID:33816054. |
cannabis use disorder (cud) is highly prevalent. |
2021-12-03 |
2023-08-13 |
Not clear |
| Deborah S Hasin, Efrat Aharonovic. Implications of Medical and Recreational Marijuana Laws for Neuroscience Research: a Review. Current behavioral neuroscience reports. vol 7. issue 4. 2021-12-03. PMID:34336547. |
review of us medical and recreational marijuana laws (mml and rml), their effects on cannabis potency, prevalence of non-medical cannabis use and cannabis use disorder (cud) in adolescents and adults, and implications for neuroscience research, given what is known about the relationship of cannabis to neurocognitive impairments and underlying brain functioning. |
2021-12-03 |
2023-08-13 |
Not clear |
| Anees Bahji, Arthi Chinna Meyyappan, Emily R Hawken, Philip G Tibb. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. The International journal on drug policy. vol 97. 2021-11-30. PMID:34062288. |
this study aimed to determine the efficacy and acceptability of pharmacotherapies for cannabis use disorder (cud). |
2021-11-30 |
2023-08-13 |
Not clear |
| Seán R Millar, Deirdre Mongan, Claire O'Dwyer, Bobby P Smyth, Ivan J Perry, Brian Galvi. Relationships between patterns of cannabis use, abuse and dependence and recent stimulant use: Evidence from two national surveys in Ireland. PloS one. vol 16. issue 8. 2021-11-30. PMID:34370775. |
we also explored how frequency of cannabis use relates to stimulant use and whether subjects with a cannabis use disorder (cud)-defined as cannabis abuse or dependence-are more likely to be recent users of cocaine or ecstasy. |
2021-11-30 |
2023-08-13 |
human |
| Karolina Kozak, Philip H Smith, Darby J E Lowe, Andrea H Weinberger, Ziva D Cooper, Rachel A Rabin, Tony P Georg. A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. The American journal of drug and alcohol abuse. vol 47. issue 5. 2021-11-26. PMID:34280058. |
while males are more likely diagnosed with cannabis use disorder (cud), females are more susceptible to developing and maintaining cud. |
2021-11-26 |
2023-08-13 |
Not clear |
| Jason P Connor, Daniel Stjepanović, Bernard Le Foll, Eva Hoch, Alan J Budney, Wayne D Hal. Cannabis use and cannabis use disorder. Nature reviews. Disease primers. vol 7. issue 1. 2021-11-25. PMID:33627670. |
cannabis use disorder (cud) is an underappreciated risk of using cannabis that affects ~10% of the 193 million cannabis users worldwide. |
2021-11-25 |
2023-08-13 |
Not clear |
| Jason P Connor, Daniel Stjepanović, Bernard Le Foll, Eva Hoch, Alan J Budney, Wayne D Hal. Cannabis use and cannabis use disorder. Nature reviews. Disease primers. vol 7. issue 1. 2021-11-25. PMID:33627670. |
the individual and public health burdens are less than those of other forms of drug use, but cud accounts for a substantial proportion of persons seeking treatment for drug use disorders owing to the high global prevalence of cannabis use. |
2021-11-25 |
2023-08-13 |
Not clear |
| Jason P Connor, Daniel Stjepanović, Bernard Le Foll, Eva Hoch, Alan J Budney, Wayne D Hal. Cannabis use and cannabis use disorder. Nature reviews. Disease primers. vol 7. issue 1. 2021-11-25. PMID:33627670. |
no pharmacotherapies have been approved for cannabis use or cud, although a number of drug classes (such as cannabinoid agonists) have shown promise and require more rigorous evaluation. |
2021-11-25 |
2023-08-13 |
Not clear |